These findings are supported by a recent clinical report by Kakeshita et al., who revealed that GRS treatment reduced urinary cAMP levels and urinary AQP2 excretion and increased urine volume in patients with congestive heart failure and preserved ejection fraction receiving tolvaptan (AVPR2 antagonist) therapy6. This evidence concerns the gene AQP2 and congestive heart failure.